

G1 The oligonucleotides P53-U and -L (encoding the p53 CTL reactive peptide KYICNSSCM SEQ ID NO. 7 (Noguchi et al., 1994 Proc. Natl. Sci. USA 91, 3171-3175) and FLU-U and -L (encoding the influenza A matrix protein peptide GILGFVFTL SEQ ID NO. 8 - reactive with influenza-specific CTLs (Gammon et al., 1992 J Immunol. 148, 7-12) were 5'-labelled with  $^{32}\text{P}$  using polynucleotide kinase and  $^{32}\text{P}$  ATP and annealed together, self-ligated at 37°C for 4 hours using T4 DNA ligase (Life Technologies, Paisley UK) and analysed on a preparative polyacrylamide sequencing gel. The bands at 180 base pairs representing 5 self-ligated copies of P53-U/L or FLU-U/L were purified, ligated to phosphorylated NotI linkers (#1127), New England Biolabs, Hitchin, UK) and digested with NotI (Pharmacia).

Please replace the paragraph on the bottom of page 11 and the top of page 12 with the following paragraph:

G2 For preparation of cytotoxic T lymphocytes (CTLs) specific for the p53-derived peptide as above, the in vivo mouse peptide immunization and sensitization procedure of Noguchi et al. (loc. cit.) was followed to produce long-term CTL lines. For testing of antibodies for ability to induce CTL activity, target mouse Sp2/0 cells (ATCC CRL-1581) were used and maintained in DMEM and 10% foetal bovine serum. For CTL assays, cells at  $5 \times 10^5$  cells/ml were labeled overnight with 20  $\mu\text{Ci}$  (7.4MBq)  $^{51}\text{Cr}$  chromate. Cells were then pelleted, washed in medium and resuspended at  $5 \times 10^5$  cells/ml in medium plus dilutions of the

antibody fragments or 10µg/ml peptide KYICNSSCM SEQ ID NO. 7 ("p53 peptide only") for 4 hours at 37°C. Cells were then repelleted, washed twice in PBS (phosphate-buffered saline) and plated at  $5 \times 10^5$  cells in 100µl in RPMI1640 medium plus 10% foetal bovine serum in 24-well plates. 100µl of CTLs were then added to give effector:target ratios of 20:1, 10:1 and 5:1 and incubated for 4 hours at 37°C. After incubation, 100µl of culture supernatant was carefully removed from each well into an eppendorf tube, centrifuged and triplicate 20µl aliquots of supernatant were counted in a scintillation counter. Percent specific release was calculated as  $[(\text{release by effector cells} - \text{spontaneous release}) / (\text{maximum release} - \text{spontaneous release})] \times 100$ .

Results were as follows:...

On page 13, please replace the second paragraph with the following paragraph:

Human cytotoxic T lymphocyte (CTLs) specific for the flu peptide GILGFVFTL SEQ ID NO. 8 were obtained from a normal HLA-A2 donor and were maintained as described by Bednarea et al., (1991 J. Immunological Methods 139, 41-47). Testing of antibodies for ability to induce CTL activity against target MCF7 cells was as for example 1 with effector:target ratios of 40:1, 20:1 and 10:1. Results were as follows:...